Pharmaceutical giant AbbVie has launched a legal challenge against the U.S. Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA), targeting what it describes as “outdated” guidelines within the federal 340B drug discount program. The lawsuit marks a significant escalation in the industry’s long-standing effort to reform the system.
Core elements of the litigation:
-
Definition Dispute: AbbVie argues that the HRSA’s reliance on 1996 guidelines to define a “patient” is overly broad. The company claims this creates loopholes, allowing healthcare entities to claim steep discounts despite minimal patient contact or through remote telehealth services with no substantial care relationship.
-
Plaintiff’s Objective: The lawsuit seeks a stricter statutory interpretation of the term “patient,” requiring individuals to have received recent and significant medical care from a provider actively managing their treatment.
-
Direct Catalyst: AbbVie initiated the suit after being denied the authority to audit specific hospitals and prescribers suspected of exploiting the program as a discretionary revenue stream.
While the 340B program was originally intended to help safety-net providers serve low-income and uninsured individuals by mandating drug discounts, pharmaceutical manufacturers are increasingly pushing for reforms. AbbVie joins other industry players like Eli Lilly and Novo Nordisk in demanding greater data transparency to prevent duplicate discounts and ensure the program serves its original altruistic purpose.